Genelux Investor Presentation Deck

Genelux Has Executed on Multiple Milestones and is Positioned for the Future Executed Milestones Executed on go public strategy and follow on with $60M raised Initation of Phase 3 Trial in PRROC Phase 2 results published in JAMA Oncology Collaboration and License agreement with Newsoara Initiation of Phase 1b/2 trial in recurrent SCLC (China) Issuance of V2ACT US Patent GENELUX Initiate Phase 2 trial in (Adjuvant Maintenance) NSCLC Enter additional regional development & commercial partnership(s) and platform collaborations Initiate Phase 1/2 trial in recurrent ovarian cancer (IV route) Initiate Ph1b/2 trial of V2ACT 30

View entire presentation